Abstract:Background and Objective center dot There is increasing demand to identify accurate and reliable molecular biomarkers for early diagnosis of neonatal sepsis. We aimed to identify and verify signature genes in neonatal sepsis through comprehensive bioinformatics analysis. Methods center dot A Gene Expression Omnibus data set was used to identify differentially expressed genes (DEGs) in patients with neonatal sepsis and healthy controls by functional and disease enrichment analysis. Gene set enrichment analysis, screening of DEGs using 2 machine algorithms, analysis of receiver operating characteristic curves, and correlation analysis with infiltrating immune cells was performed. Results center dot We identified 433 DEGs: 144 downregulated and 289 upregulated. Gene Ontology analysis identified DEGs for T cell activation, positive regulation of cytokine production, secretory granule cavity, cytoplasmic vesicle cavity, immune receptor activity, and antioxidant activity. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis identified DEGs for hematopoietic cell lineage, cytokine-cytokine receptor interaction, and coronavirus disease (COVID-19). Disease Ontology analysis identified DEGs for hematopoietic system diseases, skin system diseases, and bacterial infectious diseases. We also gained understanding of the enrichment of various functions and pathways by gene set enrichment analysis. In the neonatal sepsis group, Gene Ontology analysis results were significant for coagulation, endocytosis, white cell migration, myeloid leukocyte-mediated immunity, and phagocytosis; KEGG analysis results were significant for chemokine signaling pathway, complement and coagulation cascade, leukocyte migration across endothelium, regulation of actin cytoskeleton, and toll-like receptor signaling pathway. We screened 2 signature DEGs (GSN and SEMA4B) using the least absolute shrinkage and selection operator and support vector machine recursive feature elimination algorithms and verified their diagnostic accuracy by receiver operating characteristic curves. We correlated GSN and SEMA4B expression levels with the infiltration levels of 22 types of immune cell. Conclusion center dot GSN and SEMA4B expression accurately predicted early-stage neonatal sepsis, which is beneficial for early clinical diagnosis and treatment.

Identifying immune signatures of sepsis to increase diagnostic accuracy in very preterm babies

nSeP: immune and metabolic biomarkers for early detection of neonatal sepsis-protocol for a prospective multicohort study

Identification and Validation of Signature Genes and Their Correlations with Infiltrated Immune Cells in Neonatal Sepsis

Serum Phenylalanine, Myo-inositol, and 1,5-Anhydrohexitol biosignature differentiate neonatal sepsis cases from controls

Early-Onset Neonatal Sepsis: Inflammatory Biomarkers and MicroRNA as Potential Diagnostic Tools in Preterm Newborns

Identification of Potential Early Diagnostic Biomarkers of Sepsis

Flow Cytometry: An Important Diagnostic Tool in Critically Ill Preterm Neonates with Suspected Sepsis

Identification of Immune-Related Key Genes as Potential Diagnostic Biomarkers of Sepsis in Children

The molecular landscape of sepsis severity in infants: enhanced coagulation, innate immunity, and T cell repression

γδ T cell profiling in a cohort of preterm infants reveals elevated frequencies of CD83+ γδ T cells in sepsis

Bedside testing to predict severe sepsis?

Application of Flow Cytometry in the Early Diagnosis of Neonatal Sepsis

Ratio of neutrophilic CD64 and monocytic HLA-DR: A novel parameter in diagnosis and prognostication of neonatal sepsis

The 'analysis of gene expression and biomarkers for point-of-care decision support in Sepsis' study; temporal clinical parameter analysis and validation of early diagnostic biomarker signatures for severe inflammation andsepsis-SIRS discrimination

Predicting sepsis severity at first clinical presentation: The role of endotypes and mechanistic signatures

A robust and generalizable immune-relatedsignature for sepsis diagnostics

A six molecule nenonatal serum metabolite biosignature has high neonatal sepsis predictability and resolves upon treatment completion.

Noninfectious influencers of early-onset sepsis biomarkers

An immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expression

Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine

Discrimination of serum metabolomics profiles in infants with sepsis, based on liquid chromatography-mass spectrometer